Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Moleculin Biotech CS (NQ: MBRX )

0.9700 USD -0.0400 (-3.96%)
Official Closing Price Updated: 7:55 PM EST, Jan 15, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,533,800
Open 0.9800
Bid (Size) 0.9510 (116)
Ask (Size) 0.9600 (3)
Prev. Close 1.010
Today's Range 0.9500 - 1.000
52wk Range 0.3200 - 1.970
Shares Outstanding 25,768,861
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Moleculin to Present at the H.C. Wainwright BioConnect 2021 Conference
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,... 
From PR Newswire
Moleculin Announces Annamycin Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas
Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses,... 
From PR Newswire

Performance

YTD
+14.10%
+14.10%
1 Month
+23.28%
+23.28%
3 Month
+19.75%
+19.75%
6 Month
-11.82%
-11.82%
1 Year
+3.91%
+3.91%

More News

Read More
Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Global Sarcoma Drugs Market Size Could Reach $1.2 Billion By 2023
From PR Newswire
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases
Tags MBRX News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Moleculin Announces FDA Permission to Begin Clinical Study of Annamycin for Sarcoma Lung Metastases
From PR Newswire
Advanced Testing Options Help Alter the Fight Against Cancer
From PR Newswire
Development of Advanced Novel AML Drugs Target Increasing Cases of Acute Myeloid Leukemia
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Development of Advanced Novel AML Drugs Target Increasing Cases of Acute Myeloid Leukemia
From PR Newswire
Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference
Tags MBRX News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Moleculin To Present Antitumor Activity of Annamycin in Combination with Ara-C in AML at American Society for Hematology Annual Conference
From PR Newswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.